Prognosis and treatment decisions in patients with breast cancer without axillary node involvement.
BACKGROUND
Every month, treatment decisions must be made for more than 6000 patients with breast cancer without axillary node involvement in the United States. Approximately 70% of these patients will survive more than 10 years after surgery and/or radiation treatment without additional systemic adjuvant therapy. If we had good methods to identify patients who are destined to have a recurrence of their disease, only those patients should receive adjuvant therapy.


METHODS
The authors reviewed the literature supporting the use of currently available prognostic factors for patients with node-negative breast cancer, and formulated a framework on which prognostic factor information can be based to help make these treatment decisions.


RESULTS
The steps involved in making treatment decisions are: use prognostic factors to determine the recurrence probability; calculate the expected treatment benefit; and weigh the expected benefits against the potential risks.


CONCLUSIONS
Prognostic factors can be used to help make treatment decisions for patients with breast cancer without axillary node involvement. However, the final treatment decision must take into account all aspects of the patient and her disease, and the physician must help the patient evaluate her prognostic factors, arrive at an understanding of her particular risk of recurrence, and weigh the potential benefits and risks of adjuvant therapy.
Department of Medicine/Oncology, University of Texas Health Science Center, San Antonio 78284-7884.
W L
WL
McGuire
A K
AK
Tandon
D C
DC
Allred
G C
GC
Chamness
P M
PM
Ravdin
G M
GM
Clark
D001365:Axilla; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D002402:Cathepsin D / Q000378:metabolism; D002455:Cell Division; D002467:Cell Nucleus / Q000473:pathology; D003657:Decision Making; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D015233:Models, Statistical; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local / Q000235:genetics; D009856:Oncogene Proteins, Viral / Q000235:genetics; D011003:Ploidies; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen / Q000032:analysis; D016019:Survival Analysis
D002402:Cathepsin D; D009856:Oncogene Proteins, Viral; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen